KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBT: 2010-2024

Historic EBT for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $97.9 million.

  • Supernus Pharmaceuticals' EBT fell 228.95% to -$58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.7 million, marking a year-over-year decrease of 128.61%. This contributed to the annual value of $97.9 million for FY2024, which is 3434.49% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its EBT stood at $97.9 million for FY2024, which was up 3,434.49% from $2.8 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year EBT high stood at $168.6 million for FY2020, and its period low was $2.8 million during FY2023.
  • Its 3-year average for EBT is $53.8 million, with a median of $60.7 million in 2022.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' EBT crashed by 95.44% in 2023, and later skyrocketed by 3,434.49% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' EBT (Yearly) stood at $168.6 million in 2020, then tumbled by 56.61% to $73.2 million in 2021, then dropped by 16.99% to $60.7 million in 2022, then tumbled by 95.44% to $2.8 million in 2023, then spiked by 3,434.49% to $97.9 million in 2024.